Literature DB >> 1130738

Intravenous delta9-Tetrahydrocannabinol: Effects of ventilatory control and cardiovascular dynamics.

L A Malit, R E Johnstone, D I Bourke, R A Kulp, V Klein, T C Smith.   

Abstract

Delta9-Tetrahydrocannabinol (THC), the active component of marijuana, was studies to determine whether it might be useful for preanesthetic medication. Ten healthy subjects received THC intravenously in logarithmically spaced incremental doses. Four subjects received a total cumulatine dose of 135 mug/kg and four others, 201 mug/kg, Two of the ten subjects discontinued the study because of anxiety reactions. Ventilatory minute volume at a controlled elevated CO2 tension, 48 plus or minus 2 (SD) torr, changed minimally with TCH, -0.49 1/min/50 per cent increase in dose. TCH shifted the ventilatory response to CO22.7 torr destrad at 20 1/min without a change in slope. Dose-related tachycardia was the most marked cardiovascular effect. Heart rates increased to more than 100/min in five of six subjects. Cardiac index increased from 4.04 plus or minus 0.62 1/min/m-2 before TCH to 6.92 plus or minus 2.34 1/min/m-2 after 134 mug/kg. Mean arterial pressure increased slightly, and total peripheral resistance fell. The cardiovascular changes suggest beta-adrenergic stimulation. Intense mental effects and anxiety prohibited higher THC doses.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1130738

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  13 in total

1.  Ventilatory-depressant effects of opioids alone and in combination with cannabinoids in rhesus monkeys.

Authors:  Peter F Weed; Lisa R Gerak; Charles P France
Journal:  Eur J Pharmacol       Date:  2018-05-26       Impact factor: 4.432

2.  The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression.

Authors:  Nathalie Niederhoffer; Karin Schmid; Bela Szabo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-23       Impact factor: 3.000

3.  The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.

Authors:  Michelle Carbuto; R Andrew Sewell; Ashley Williams; Kim Forselius-Bielen; Gabriel Braley; Jacqueline Elander; Brian Pittman; Ashley Schnakenberg; Savita Bhakta; Edward Perry; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2011-08-16       Impact factor: 4.530

4.  Effects of delta1-trans-tetrahydrocannabinol on mechanical performance of isolated heart muscle preparations.

Authors:  J D Graham; A C Grey; A H Henderson; M J Lewis
Journal:  Br J Pharmacol       Date:  1978-01       Impact factor: 8.739

5.  Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects.

Authors:  A W Zuardi; I Shirakawa; E Finkelfarb; I G Karniol
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  [Respiratory failure due to delta-9-tetrahydrocannabinol in a tetraplegic patient].

Authors:  M Neuburger; M Schley; M Schmelz; G Schuepfer; C Konrad
Journal:  Schmerz       Date:  2006-11       Impact factor: 1.107

7.  Analysis of the respiratory effects of cannabinoids in rats.

Authors:  Karin Schmid; Nathalie Niederhoffer; Bela Szabo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-10       Impact factor: 3.000

8.  Cannabinoid receptor activation in the nucleus tractus solitaries produces baroreflex-like responses in the rat.

Authors:  Murat S Durakoglugil; Hakan S Orer
Journal:  Int J Biomed Sci       Date:  2008-09

Review 9.  Surgical considerations of marijuana use in elective procedures.

Authors:  Henry B Huson; Tamara Marryshow Granados; Yvonne Rasko
Journal:  Heliyon       Date:  2018-09-15

Review 10.  Priming primary care providers to engage in evidence-based discussions about cannabis with patients.

Authors:  Devan Kansagara; William C Becker; Chelsea Ayers; Jeanette M Tetrault
Journal:  Addict Sci Clin Pract       Date:  2019-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.